SCHEMBL16092558

SCHEMBL16092558

CC(C)c1c(-c2cccc(C(C)(C)O)c2)[nH]c2c(C#N)cnn2c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM5A P29375 8/20 0.44
▸ KDM5B Q9UGL1 5/20 0.37
▸ KDM5C P41229 2/20 0.37
▸ KDM4C Q9H3R0 2/20 0.37
▸ KDM6B O15054 1/20 0.37
▸ KDM5D Q9BY66 1/20 0.37
▸ PHF8 Q9UPP1 1/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ KDM4D Q6B0I6 1/20 0.36
▸ GABRA1 P14867 1/20 0.35
▸ GABRG2 P18507 1/20 0.35
▸ GABRB3 P28472 1/20 0.35
▸ GABRA5 P31644 1/20 0.35
▸ GABRA3 P34903 1/20 0.35
▸ PIK3CD O00329 2/20 0.35
▸ TGFBR1 P36897 1/20 0.34
▸ PLAT P00750 2/20 0.34
▸ TLR9 Q9NR96 1/20 0.34
▸ TLR8 Q9NR97 1/20 0.34
▸ TLR7 Q9NYK1 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16092254 0.90 KDM5A (0.55) KDM5AKDM5BKDM5CKDM4CKDM6B
SCHEMBL16092323 0.88 KDM5A (0.40) KDM5AKDM5BKDM5CKDM4CKDM6B
SCHEMBL16092293 0.86 KDM5A (0.39) KDM5AKDM5BKDM5CKDM4CKDM6B
SCHEMBL16092493 0.86 KDM5B (0.48) KDM5AKDM5BKDM5CKDM4CKDM6B
SCHEMBL16092243 0.86 KDM5A (0.43) KDM5AKDM5BKDM5CKDM4CKDM6B
SCHEMBL16092255 0.85 KDM5B (0.42) KDM5AKDM5BKDM5CKDM4CKDM6B
SCHEMBL17085740 0.85 KDM5A (0.39) KDM5AKDM5BKDM5CKDM4CKDM6B
SCHEMBL16050761 0.85 KDM5A (0.41) KDM5AKDM5BKDM5CKDM4CKDM6B
SCHEMBL16092249 0.84 KDM5A (0.47) KDM5AKDM5BKDM5CKDM4CKDM6B
SCHEMBL16092448 0.84 KDM5B (0.46) KDM5AKDM5BKDM5CKDM4CKDM6B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10035801-B2 Pyrazolo compounds and uses thereof GENENTECH, INC. (US) 2018-07-31 — — US disclosed
US-10035801-B2 Pyrazolo compounds and uses thereof GENENTECH, INC. (US) 2018-07-31 — — US disclosed
US-20160060267-A1 PYRAZOLO COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2016-03-03 — — US disclosed
US-20160060267-A1 PYRAZOLO COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2016-03-03 — — US disclosed
WO-2015135094-A1 THERAPEUTIC COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2015-09-17 — — WO disclosed
WO-2014139326-A1 PYRAZOLO COMPOUNDS AND USES THEREOF GENENTECH, INC. (US) 2014-09-18 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10035801-B2 Pyrazolo compounds and uses thereof KDM5A, KDM5C, KDM5B KDM5A 1/4885KDM5B 3/4885KDM5C 2/4885
US-20160060267-A1 PYRAZOLO COMPOUNDS AND USES THEREOF KDM5A, KDM5C, KDM5B KDM5A 1/4885KDM5B 3/4885KDM5C 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback